AU2011323458B2 - Compositions and methods for the delivery of therapeutics - Google Patents

Compositions and methods for the delivery of therapeutics Download PDF

Info

Publication number
AU2011323458B2
AU2011323458B2 AU2011323458A AU2011323458A AU2011323458B2 AU 2011323458 B2 AU2011323458 B2 AU 2011323458B2 AU 2011323458 A AU2011323458 A AU 2011323458A AU 2011323458 A AU2011323458 A AU 2011323458A AU 2011323458 B2 AU2011323458 B2 AU 2011323458B2
Authority
AU
Australia
Prior art keywords
nanoparticle
rtv
drug
atv
nanoart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011323458A
Other languages
English (en)
Other versions
AU2011323458A1 (en
Inventor
Howard E. Gendelman
Alexander V. Kabanov
Xin-Ming Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska System
Original Assignee
University of Nebraska Lincoln
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska Lincoln, University of Nebraska System filed Critical University of Nebraska Lincoln
Publication of AU2011323458A1 publication Critical patent/AU2011323458A1/en
Application granted granted Critical
Publication of AU2011323458B2 publication Critical patent/AU2011323458B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011323458A 2010-11-02 2011-11-02 Compositions and methods for the delivery of therapeutics Ceased AU2011323458B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40937210P 2010-11-02 2010-11-02
US61/409,372 2010-11-02
US201161526976P 2011-08-24 2011-08-24
US61/526,976 2011-08-24
PCT/US2011/058929 WO2012061480A2 (en) 2010-11-02 2011-11-02 Compositions and methods for the delivery of therapeutics

Publications (2)

Publication Number Publication Date
AU2011323458A1 AU2011323458A1 (en) 2013-05-23
AU2011323458B2 true AU2011323458B2 (en) 2017-02-23

Family

ID=46025083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011323458A Ceased AU2011323458B2 (en) 2010-11-02 2011-11-02 Compositions and methods for the delivery of therapeutics

Country Status (8)

Country Link
US (1) US20130236553A1 (enExample)
EP (1) EP2635260A4 (enExample)
JP (1) JP2013542945A (enExample)
AU (1) AU2011323458B2 (enExample)
CA (1) CA2816123A1 (enExample)
MX (1) MX2013004981A (enExample)
RU (1) RU2632445C2 (enExample)
WO (1) WO2012061480A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
ITRM20120350A1 (it) * 2012-07-19 2014-01-20 Univ Degli Studi Milano Nanocostrutti con attività farmacologica.
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
EP2983789A4 (en) * 2013-04-11 2016-11-02 Univ Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2015108945A2 (en) * 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
EP3110422A4 (en) * 2014-02-24 2017-09-06 Board of Regents of the University of Nebraska Compositions and methods for the delivery of therapeutics
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20160346219A1 (en) * 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
EP3190176A1 (en) 2016-01-11 2017-07-12 IMBA-Institut für Molekulare Biotechnologie GmbH Method for tissue culture development on scaffold and differentiated tissue culture
US9872859B2 (en) * 2016-02-20 2018-01-23 The Florida International University Board Of Trustees Materials and methods for targeting therapeutic compositions to gut-associated lymphoid tissue (GALT)
ES3035041T3 (en) 2016-06-23 2025-08-27 Viiv Healthcare Co Compositions and methods for the delivery of therapeutics
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
EP4234560A3 (en) 2018-10-22 2023-09-13 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN113382737B (zh) 2018-11-29 2025-06-03 内布拉斯加大学董事会 抗病毒前药及其纳米制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6068858A (en) * 1997-02-13 2000-05-30 Elan Pharma International Limited Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2000066090A1 (en) * 1999-05-04 2000-11-09 Biotech Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
US20050048002A1 (en) * 2003-06-24 2005-03-03 Barrett Rabinow Method for delivering drugs to the brain
WO2010009075A1 (en) * 2008-07-14 2010-01-21 The University Of North Carolina At Chapel Hill Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006130958A (ru) * 2004-01-29 2008-03-10 Бакстер Интернэшнл Инк. (Us) Наносуспензии антиретровирусных агентов для улучшенной доставки в центральную нервную систему
RU2404988C2 (ru) * 2006-04-24 2010-11-27 Нм Тек Лтд. Наноматериалз Энд Микродевайсиз Текнолоджи Функциональные наноматериалы с антибактериальной и антивирусной активностью
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6068858A (en) * 1997-02-13 2000-05-30 Elan Pharma International Limited Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2000066090A1 (en) * 1999-05-04 2000-11-09 Biotech Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
US20050048002A1 (en) * 2003-06-24 2005-03-03 Barrett Rabinow Method for delivering drugs to the brain
WO2010009075A1 (en) * 2008-07-14 2010-01-21 The University Of North Carolina At Chapel Hill Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds

Also Published As

Publication number Publication date
RU2632445C2 (ru) 2017-10-04
JP2013542945A (ja) 2013-11-28
WO2012061480A2 (en) 2012-05-10
US20130236553A1 (en) 2013-09-12
AU2011323458A1 (en) 2013-05-23
RU2013122656A (ru) 2014-12-10
EP2635260A4 (en) 2014-07-09
WO2012061480A3 (en) 2013-01-03
MX2013004981A (es) 2013-11-04
CA2816123A1 (en) 2012-05-10
EP2635260A2 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
RU2632445C2 (ru) Композиции и способы доставки терапевтических средств
Puligujja et al. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections
EP1310244A2 (en) Compositions comprising an anticancer agent and a polyether block copolymer
EP4299133A2 (en) Compositions and methods for the delivery of therapeutics
US11136339B2 (en) Dihydroartemisinin diploid derivative, pharmaceutical composition thereof, and application
KR20240125700A (ko) 항바이러스성 프로드러그 및 이의 나노제제
US20170165271A1 (en) Compositions and Methods for the Delivery of Therapeutics
Zhang et al. Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection
Li et al. Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy
US11311545B2 (en) Compositions and methods for the delivery of therapeutics
Surve et al. Long-acting efavirenz and HIV-1 fusion inhibitor peptide co-loaded polymer–lipid hybrid nanoparticles: statistical optimization, cellular uptake, and in vivo biodistribution
US20160136105A1 (en) Compositions and Methods for the Delivery of Therapeutics
Jaimalai et al. Drug delivery system targeting CD4+ T Cells for HIV-1 latency reactivation towards the viral eradication
US11458136B2 (en) Antiviral prodrugs and formulations thereof
US20240398981A1 (en) Novel nanoparticles of antiretroviral drugs, their preparation and their use for the treatment of viral infections
Yao et al. A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy
Wu Development of a novel nano emulsion system intended for targeted drug delivery to HIV lymphocyte reservoir
Patel Formulation Development and Evaluation of Transdermal Delivery Systems for Some Drugs Used in Arthritis
Mandal et al. Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study. Nanomaterials 2022, 12, 1942
WO2026026701A1 (zh) 非洛地平脂质体及其制备和应用
Gong A Novel Elvitegravir Nanoformulation for Drug Delivery Across the Blood-Brain Barrier to Suppress HIV-1 in Macrophages and Microglia
WO2024167958A1 (en) Antigen-capturing nanoparticles and formulations for immunotherapy
Mandal et al. Targeted immuno-antiretroviral HIV therapeutic approach to provide dual protection and boosts cellular immunity: A proof-of-concept study
Nowacek Development of a macrophage-mediated delivery system for crystalline antiretroviral nanoparticles
Zhao Pharmacokinetics, biodistribution and intratumoral distribution of Celludo nanoparticles

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired